Track Your Retatrutide Journey
Retatrutide is an investigational triple-action GLP-1 medication activating three receptors — GLP-1, GIP, and glucagon — currently in clinical trials. Over 2,300 MeAgain subscribers are already tracking retatrutide via the custom medication feature, logging doses, side effects, and estimated levels as this promising molecule advances through trials. MeAgain helps you feel like you again.
Last updated March 2026
What Features Does a Retatrutide Tracking App Offer?
Custom Medication Logging for Investigational GLP-1s
Retatrutide is not yet FDA-approved, so MeAgain tracks it through the custom medication feature. Add your dose, frequency, and injection schedule — and MeAgain logs each injection with timestamps, site rotation, and a side effect prompt. Your retatrutide history is always complete and portable.
Estimated Levels Chart for Triple-Agonist Dosing
MeAgain's estimated medication levels bar chart is built on GLP-1 pharmacokinetic curves. For retatrutide's weekly injection schedule, the chart shows your estimated active medication level across the 7-day cycle — helping you understand the peak-and-trough pattern and when to expect heightened or reduced appetite suppression.
Side Effect Tracking Across Dose Escalation
Clinical trial data for retatrutide shows dose-dependent side effects similar to other GLP-1 agents. Log nausea, fatigue, injection site reactions, and custom symptoms with a severity slider at each dose step. The timeline view lets you see exactly how triple-agonist side effects track against your titration progress.
Understanding Retatrutide: The Investigational Triple-Action GLP-1
Retatrutide (LY3437943) is an investigational once-weekly injectable GLP-1 medication developed by Eli Lilly. Unlike semaglutide (single GLP-1 agonist) or tirzepatide (dual GLP-1/GIP agonist), retatrutide activates three receptors simultaneously — GLP-1, GIP, and the glucagon receptor — making it a "triple agonist." It is not FDA-approved and is currently in Phase 3 clinical trials.
| Semaglutide | Tirzepatide | Retatrutide (Investigational) | |
|---|---|---|---|
| Mechanism | Single agonist | Dual agonist | Triple agonist |
| Receptors activated | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Dosing | Weekly injection | Weekly injection | Weekly injection (trials) |
| FDA-approved | Yes (Ozempic/Wegovy) | Yes (Mounjaro/Zepbound) | No — investigational |
| Brands | Ozempic, Wegovy | Mounjaro, Zepbound | None yet |
What the Glucagon Receptor Addition May Mean
- Glucagon receptor activation increases energy expenditure and fat mobilization
- Phase 2 data showed up to 24% weight loss at 48 weeks — higher than current approved agents
- Side effect profile appears similar to other GLP-1 agents (nausea, GI symptoms)
- Results are from clinical trials — individual outcomes vary significantly
- Phase 3 trials are ongoing; FDA approval timeline is not yet confirmed
MeAgain tracks retatrutide via the custom medication feature — you set your dose, frequency, and titration schedule, and the app logs every injection, side effect, and weight data point so your full retatrutide history is documented as the clinical landscape evolves.
Retatrutide is an investigational medication and is NOT FDA-approved. It is available only through clinical trials. This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, changing, or stopping any medication.
Why Track an Investigational Medication with MeAgain?
Document Your Experience While the Science Develops
Retatrutide is in active Phase 3 trials — which means the clinical picture is still forming. Tracking your dose, side effects, and outcomes creates a personal dataset that's useful for your health partner and gives you a factual record of how the triple-agonist mechanism is working for you specifically.
Join 2,300+ Subscribers Already Tracking Retatrutide
MeAgain already has over 2,300 subscribers tracking retatrutide via the custom medication feature. That means the patterns being documented — side effect severity curves, weight trend timelines, dose escalation experiences — are real-world data from people on the same investigational molecule.
A Portable Record for Every Clinical Visit
If you're in a retatrutide trial or accessing it through a compounding pharmacy, your health partner needs accurate dose and side effect data. MeAgain's log captures every injection, symptom, and weight measurement so you arrive at every appointment with a complete, timestamped record — not a rough memory.
What Are Retatrutide Users Tracking?
Join the Community
Subscribers on retatrutide say the most important thing they track is the dose-escalation window — when GI side effects peak and when they begin to ease. The estimated levels chart and side effect timeline give a clear picture of the adjustment period that generic health apps can't provide for custom medications.
Over 286,000 people are tracking their GLP-1 journey with MeAgain — including 2,300+ subscribers already logging retatrutide doses, side effects, and weight progress. For eligible subscribers, zero markup compounded semaglutide is available in-app at $123/mo with no commitments.
What Our Users Say
Retatrutide Tracker - Your Questions Answered
Retatrutide is NOT FDA-approved and is only available through clinical trials. It is an investigational once-weekly injectable developed by Eli Lilly that activates three receptors — GLP-1, GIP, and glucagon. Phase 3 clinical trials are ongoing. MeAgain supports tracking retatrutide via the custom medication feature.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.